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OBJECTIVES Using proton magnetic resonance spectroscopy, we investigated cerebral metabolism and its
determinants in congestive heart failure (CHF), and the effects of cardiac transplantation on
these measurements.
BACKGROUND Few data are available about cerebral metabolism in CHF.
METHODS Fifty patients with CHF (ejection fraction #35%) and 20 healthy volunteers were included
for this study. Of the patients, 10 patients underwent heart transplantation. All subjects
performed symptom-limited bicycle exercise test. Proton magnetic resonance spectroscopy
(1H MRS) was obtained from localized regions (8 to 10 ml) of occipital gray matter (OGM)
and parietal white matter (PWM). Absolute levels of the metabolites (N-acetylaspartate,
creatine, choline, myo-inositol) were calculated.
RESULTS In PWM only creatine level was significantly lower in CHF than in control subjects, but in
OGM all four metabolite levels were decreased in CHF. The creatine level was independently
correlated with half-recovery time and duration of heart failure symptoms in PWM (r 5
20.56, p , 0.05), and with peak oxygen consumption and serum sodium concentration in
OGM (r 5 0.58, p , 0.05). Cerebral metabolic abnormalities were improved after successful
cardiac transplantation.
CONCLUSIONS This study shows that cerebral metabolism is abnormally deranged in advanced CHF and it
may serve as a potential marker of the disease severity. (J Am Coll Cardiol 1999;33:
1196–202) © 1999 by the American College of Cardiology
Congestive heart failure (CHF) is a common, disabling
disorder with high morbidity and mortality. A complex
series of compensatory mechanisms occurs to maintain
perfusion to vital organs in response to the progressive
reduction of cardiac output (1–5). The brain is a critical
organ, but it should also adjust to this change as heart failure
becomes chronic. Cognitive dysfunction is a common prob-
lem experienced by patients with CHF (6–10). It may result
from adaptation failure of the brain, which leads to poor
quality of life and eventually to death. Therefore, cerebral
adaptation mechanisms certainly deserve to be considered in
clinical assessment of CHF patients.
Proton magnetic resonance spectroscopy (1H MRS) is a
sensitive technique to detect metabolic changes of the brain
(11). For this reason, 1H MRS has been convincingly used
to assess metabolic changes of the brain in various clinical
diseases (11–17). Cerebral metabolism is presumably abnor-
mal due to overall and local disturbances of cerebral blood
flow in CHF (18,19). However, there is a lack of informa-
tion regarding the cerebral metabolism in CHF. We as-
sumed that cerebral metabolism is abnormally deranged,
and it may represent the disease severity in CHF.
To address this hypothesis, we investigated cerebral
metabolism and its determinants in patients with advanced
CHF and examined the effects of cardiac transplantation on
these measurements using 1H MRS examination.
METHODS
Study group. Fifty consecutive patients with advanced
CHF (left ventricular ejection fraction #35%) and 20
healthy volunteers were prospectively included for this
study. All patients were clinically stable with medical
treatment in the last four weeks; 50 patients were treated
with digoxin, 48 patients with angiotensin-converting en-
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zyme inhibitors and 46 patients with diuretics. Of the
patients, 10 patients underwent cardiac transplantation.
Patients were excluded if they had cerebrovascular disease,
history of drug or alcohol abuse, chronic liver disease,
chronic renal failure or any other diseases affecting cognitive
function. The study was approved by the ethics committee
of the Asan Medical Center, and no adverse events were
recorded in any individuals undergoing the protocol. All
subjects gave written informed consent to participate in the
study.
Clinical and laboratory evaluation. All subjects were eval-
uated using a standardized protocol including patient his-
tory, physical examination and laboratory studies on the day
of 1H MRS examination. New York Heart Association
(NYHA) functional class was also determined on the day of
1H MRS examination.
Echocardiography and multigated blood pool scan.
Two-dimensional Doppler echocardiography was per-
formed with standard techniques in all subjects, and left
ventricular ejection fraction was measured using multigated
blood pool scan.
Exercise test. Exercise test was performed in all subjects on
an upright electromagnetically braked bicycle (MedGraph-
ics, Cardiopulmonary Diagnostic Systems, St. Paul, Min-
nesota) using a ramp protocol (10-W ramp with an incre-
ment of 10 W/min in CHF patients; 20-W ramp with an
increment of 20 W/min in normal control subjects) in the
morning after a light standard meal. Exercise test was
terminated at a point when subjects were unable to continue
due to dyspnea or fatigue. Subjects remained on the bicycle
after the exercise during the recovery phase until the
respiratory exchange ratio was less than 1 for 20 s. Respi-
ratory gas analysis was carried out with a computerized
system (MedGraphics, Cardiopulmonary Diagnostic Sys-
tems, St. Paul, Minnesota), calibrated with standard gas of
known concentration before each test. The peak oxygen
consumption was defined as highest 15-s average oxygen
consumption. Recovery kinetics are characterized by mea-
suring the half-recovery time, which is the time required for
a 50% fall in the peak value (20,21).
Proton magnetic resonance spectroscopic examination.
All subjects underwent 1H MRS examination of the brain, and
patients receiving cardiac transplantation were asked to have a
follow-up examination after two months. Localized in vivo 1H
MRS was performed on a GE 1.5-T SIGNA system equipped
with shielded gradients (General Electric Medical Systems,
Milwaukee, Wisconsin). Proton magnetic resonance spectros-
copy was performed following a T1-weighted magnetic reso-
nance imaging. Image-guided stimulated echo acquisition
mode spectra were obtained in two locations (voxel volume, 8
to 10 ml), a mostly parietal white matter (PWM) voxel and a
mostly occipital gray matter (OGM) voxel. The spectral
acquisition parameters were echo time of 30 ms, repetition
time of 3 s and 36 averages with PROBE (proton brain
examination) (General Electric Medical Systems, Milwaukee,
Wisconsin). A three-pulse chemical shift selective sequence
was used for suppression of the water signal. All raw PROBE
data were transferred to a Sun Spark-10 workstation (SUN
Computer, Sunnyvale, California) and processed according to
the method described by Kreis et al. (12). Peaks were identified
with known chemical shifts: N-acetylaspartate (NAA),
2.02 ppm; creatine (Cr), 3.03 ppm; choline (Cho), 3.22 ppm
(choline-containing compounds), and myo-inositol (mI),
3.56 ppm. The absolute concentrations of the cerebral metab-
olites were calculated using the brain water signal as an internal
reference from the PROBE data (22–24) and expressed in
mmol/kg of wet weight. The reference brain water signals used
in our calculation were 64% in PWM and 76% in OGM, as
calculated according to the method described by Ernst et al.
(23) for normal volunteers. All spectra were reviewed blindly to
the clinical data.
Statistical analysis. Statistical analysis was performed us-
ing SPSS 7.5 for Windows. Data were expressed as mean 6
SD for continuous variables, and frequencies for the cate-
gorical variables. Continuous variables were compared by
unpaired Student t test, categorical variables by chi-square
test and serial changes of cerebral metabolites before and
after cardiac transplantation by paired Student t test. Linear
regression analysis was performed on all variables to identify
determinants of the cerebral metabolite levels, and variables
found to be significant by univariate analysis were entered
into a stepwise multiple linear regression analysis to deter-
mine their independent relationship to the cerebral metab-
olite levels. A p value , 0.05 was considered statistically
significant.
RESULTS
Baseline characteristics. The baseline clinical and labora-
tory findings are summarized in Table 1. The causes of
CHF were dilated cardiomyopathy in 45 patients, valvular
heart disease in three patients and ischemic heart disease in
two patients. Age, gender and mean blood pressure were
similar between the two groups. However, there were
significant differences in heart rate, NYHA functional class,
Abbreviations and Acronyms
CHF 5 congestive heart failure
Cho 5 choline
Cr 5 creatine
1H MRS 5 proton magnetic resonance spectroscopy
mI 5 myo-inositol
NAA 5 N-acetylaspartate
NYHA 5 New York Heart Association
OGM 5 occipital gray matter
PWM 5 parietal white matter
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rhythm status, left ventricular function or dimension, exer-
cise capacity and serum sodium or osmolar concentrations
between the two groups.
Magnetic resonance image. The brain was normal in all
study subjects on magnetic resonance imaging. Cerebral
atrophy, cerebral infarct or tumors were not seen in any
subjects included for this study.
Proton magnetic resonance spectroscopy. METABOLIC
CHANGES IN PWM. Typical 1H MRS spectra obtained from
a healthy volunteer and a patient with CHF are shown in
Figure 1, which represent a markedly decreased creatine
peak, but normal peaks of other metabolites in the CHF
patient compared with those in the normal control subject.
The creatine level in PWM was significantly decreased in
CHF compared with that in the normal control subjects,
but levels of other metabolites (NAA, Cho and mI) were
not different between the two groups (Table 2). Factors
associated with a decreased level of creatine were half-
recovery time, peak oxygen consumption, duration of heart
failure symptoms, left ventricular function and NYHA
functional class (Table 3). However, half-recovery time and
duration of heart failure symptoms were independently
associated with creatine level by multivariate regression
analysis (r 5 20.56, p , 0.05). Interestingly, creatine level
was significantly lower in patients with heart failure dura-
tion more than six months (n 5 18) than in patients with
duration less than six months (6.44 6 0.90 mmol/kg vs.
6.94 6 0.60, respectively, p , 0.05).
Table 1. Baseline Clinical Characteristics
Characteristics CHF (n 5 50) Control (n 5 20)
Age (yr) 41.8 6 14.5 39.0 6 14.1
Sex (M/F) 38/12 15/5
Heart rate (beats/min) 85.1 6 16.1 68.2 6 8.1*
Mean blood pressure (mm Hg) 83.2 6 13.8 85.1 6 8.8
NYHA functional class (n) II (8), III (29), IV (13) I (20)*
Etiology of CHF
Dilated cardiomyopathy 45 (90%) —
Valvular heart disease 3 (6%) —
Ischemic heart disease 2 (4%) —
Atrial fibrillation 10 (20%) 0 (0%)*
LV ejection fraction (%) 19.0 6 5.2 65.0 6 3.5*
LV systolic dimension (mm) 64.2 6 9.2 25.0 6 5.0*
LV diastolic dimension (mm) 72.1 6 11.7 36.0 6 4.0*
Peak oxygen consumption (ml/kg/min) 15.9 6 4.6 37.7 6 4.5*
Half-recovery time (s) 138.9 6 62.9 50.0 6 6.5*
Serum sodium (mEq/L) 138.0 6 3.6 140.1 6 2.5*
Serum osmolarity (mmol/L) 287.6 6 7.5 292.5 6 6.1†
*p , 0.01. †p , 0.05.
CHF 5 congestive heart failure; LV 5 left ventricle; NYHA 5 New York Heart Association.
Figure 1. Typical proton magnetic resonance spectroscopy spectra
acquired from a parietal white matter region. The creatine peak is
significantly reduced in congestive heart failure (arrow) compared
with that in a normal control subject. Cho 5 choline; Cr 5
creatine; mI 5 myo-inositol; NAA, N-acetylaspartate.
Table 2. Cerebral Proton Magnetic Resonance
Spectroscopic Data
Cerebral Metabolite
Levels
CHF
(n 5 50)
Control
(n 5 20)
Occipital gray matter
(mmol/kg)
Choline 1.44 6 0.23 1.62 6 0.16*
Creatine 7.60 6 1.32 8.86 6 0.52*
Myo-inositol 5.54 6 1.38 6.87 6 1.14*
N-acetylaspartate 9.72 6 1.52 10.57 6 1.23†
Parietal white matter
(mmol/kg)
Choline 1.66 6 0.28 1.71 6 0.23
Creatine 6.61 6 0.93 7.47 6 0.69*
Myo-inositol 5.52 6 1.27 5.46 6 0.90
N-acetylaspartate 9.31 6 1.14 9.45 6 1.18
*p , 0.01. †p , 0.05.
CHF 5 congestive heart failure.
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METABOLIC CHANGES IN OCCIPITAL GRAY MATTER. In
contrast to PWM, creatine, choline and myo-inositol levels
in OGM were markedly decreased in CHF compared with
those in normal control subjects (Fig. 2, Table 2). In
addition, NAA level in OGM was also decreased in CHF
(Table 2). The creatine level was significantly related to
peak oxygen consumption, half-recovery time, serum so-
dium or osmolar concentration and NYHA functional class
(Table 3). However, peak oxygen consumption and serum
sodium concentration were independent predictors of the
occipital Cr level by multivariate regression analysis (r 5
0.58, p , 0.05). N-acetylaspartate level was associated with
serum sodium concentration (r 5 0.34, p , 0.05) and peak
oxygen consumption (r 5 0.30, p , 0.05). In the multivar-
iate analysis, however, only serum sodium concentration
remained a significant predictor of NAA level. The Cho
level was independently correlated with serum sodium
concentration and NYHA functional class (r 5 0.47, p ,
0.05) and the myo-inositol level with serum osmolarity (r 5
0.42, p , 0.01).
Effect of cardiac transplantation on cerebral metabolites.
Figure 2 shows characteristic change of creatine peak in
PWM (a) and OGM (b) after successful cardiac transplan-
tation, and the serial changes of all metabolite levels before
and two months after successful cardiac transplantation are
listed in Table 4. The levels of Cr/Cho in PWM, and of
NAA and Cr in OGM were significantly improved after
Table 3. Factors Associated With a Decreased Level of Creatine in 50 Patients With CHF
(Univariate Analysis)
Variables
PWM OGM
r
Value
p
Value
r
Value
p
Value
pVO2 (ml/kg/min) 0.49 , 0.01 0.48 , 0.01
Half-recovery time (s) 20.50 , 0.01 20.37 , 0.05
Duration of symptoms (months) 20.35 , 0.05 20.16 NS
NYHA functional class 20.32 , 0.05 20.28 , 0.05
LV ejection fraction 0.32 , 0.05 0.10 NS
LV systolic dimension 20.34 , 0.05 20.10 NS
Serum sodium concentration 0.26 NS 0.42 , 0.01
Serum osmolarity 0.25 NS 0.35 , 0.05
CHF 5 congestive heart failure; LV 5 left ventricle; PWM 5 parietal white matter; OGM 5 occipital gray matter; pVO2 5
peak oxygen consumption.
Figure 2. Effects of cardiac transplantation on the proton magnetic
resonance spectroscopy spectra. Spectra are obtained from an,
18-year-old male patient before and 2 months after successful
cardiac transplantation. The creatine peaks in parietal white matter
(a) and occipital gray matter (b) are remarkably increased after
cardiac transplantation (arrows). The peaks of mI, Cho and NAA
in occipital gray matter are slightly increased after cardiac trans-
plantation (b). Cho 5 choline; Cr 5 creatine; mI 5 myo-inositol;
NAA 5 N-acetylaspartate.
Table 4. Changes of Cerebral Metabolites Levels in 10 Patients
With Cardiac Transplantation
Cerebral
Metabolites
Before
Transplantation
After
Transplantation
Occipital gray matter
(mmol/kg)
Choline 1.38 6 0.27 1.54 6 0.30
Creatine 6.84 6 1.06 7.65 6 1.27*
Myo-inositol 5.08 6 1.70 5.79 6 1.00
N-acetylaspartate 9.04 6 1.88 9.82 6 1.81*
Parietal white matter
(mmol/kg)
Choline 1.63 6 0.22 1.94 6 0.33*
Creatine 6.08 6 0.72 6.95 6 0.74*
Myo-inositol 4.88 6 1.11 5.45 6 0.73
N-acetylaspartate 8.85 6 1.02 9.09 6 1.40
*p , 0.05.
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successful cardiac transplantation (p , 0.05). Myo-inositol
and choline levels in OGM were also increased after
successful cardiac transplantation, but this did not achieve
statistical significance.
DISCUSSION
In the present study we demonstrate that cerebral metabo-
lism is abnormally deranged in patients with advanced
CHF, but improves after successful cardiac transplantation.
Furthermore, we show that the spectroscopic abnormalities
are related to exercise capacity and duration of heart failure
symptoms, thereby serving as a potential marker for the
disease severity. These findings may provide a neurochem-
ical basis for the understanding of cognitive dysfunction in
advanced CHF (6–10).
Proton magnetic resonance spectroscopy is a highly
sensitive and reliable method that allows us noninvasively to
investigate metabolic changes in a well localized region of
the brain in vivo and, therefore, provides quantitative
information on regional cerebral metabolism. In most clin-
ical studies the results of 1H MRS have been reported as
metabolite ratio measurements, as opposed to quantitation
of metabolite levels (11–17,25). Creatine has been used as
an internal standard assuming that the creatine level is
constant in the brain. However, its levels can be changed
according to the nature of clinical diseases as shown in this
study. Furthermore, metabolite ratio measurements may be
misleading in cases in which all metabolites change simul-
taneously in the same direction. In contrast, quantitation of
absolute metabolite levels overcomes this limitation. For
these reasons, we analyzed all data in terms of absolute
metabolite levels.
Metabolic changes of parietal white matter. Creatine
level in PWM was remarkably decreased in CHF, but
recovered after successful cardiac transplantation. In con-
trast, levels of other metabolites (N-acetylaspartate, choline
and myo-inositol) were not different between the two
groups. These findings suggest that patients with CHF have
a cerebral energy deficit in the PMW region because
creatine is critical for cerebral energy metabolism and
reserve. Cerebral metabolite levels may be affected by
osmolar status (26). However, myo-inositol level, a marker
of reversible cerebral osmolyte, was not significantly
changed in CHF. Furthermore, serum sodium concentra-
tion was mildly decreased in most of the patients. Therefore,
we suppose that decreased creatine level in PWM may be a
characteristic 1H MRS pattern of CHF, representing cere-
bral energy deficit. The lactate peak, an end product of
anaerobic glycolysis, was not observed in this study, which
may represent metabolic compensation of the brain to
chronic cerebral hypoperfusion. Interesting, and somewhat
unexpected, was an increase in parietal Cho level two
months after successful cardiac transplantation. The mech-
anism underlying this puzzling overshoot phenomenon
remains unclear, which requires further studies.
Creatine level in PWM was correlated with exercise
capacity and duration of heart failure symptoms. Exercise
capacity has been demonstrated to be impaired in parallel
with the severity of the disease, and was reported to be an
important determinant of prognosis in patients with CHF
(1–3,20,21). In these regards, decreased level of creatine in
PWM region seems to reflect chronicity of the disease, and
severity of left ventricular dysfunction in patients with
CHF.
Metabolic changes of occipital gray matter. Metabolites
in gray matter were more dramatically changed than those
in PWM. These may result from regional differences of
susceptibility to chronic cerebral hypoperfusion and/or os-
molar changes. Metabolic changes were more closely related
to serum osmolarity in gray matter than in white matter.
However, not all of the decreased level in metabolites can be
explained by the changes in serum osmolarity, because
hyposmolar state was mild in most of the patients, and the
creatine levels were also independently correlated to peak
oxygen consumption. In general, metabolic abnormalities
appear to develop earlier, and progress more rapidly, in gray
matter than in white matter. However, it remains to be
elucidated whether diffuse metabolic abnormality of the
brain is a distinct occipital 1H MRS pattern in CHF.
N-acetylaspartate was suggested as a neuronal marker,
loss of NAA being generally an accompaniment of neuronal
loss (11). Until now, it is still controversial whether loss of
NAA can be reversible according to the disease activity in a
clinical setting. Interestingly, our study shows that it can be
recovered after successful cardiac transplantation. However,
this must be cautiously interpreted as signs of neuronal
recovery because several other metabolites can contribute to
the spectral region of NAA, such as glutamate, aspartate
and others.
It is interesting that the 10 patients who received trans-
plantation had lower cerebral metabolite levels compared
with those of the total CHF patients before their transplan-
tation. After transplantation, their metabolic level, in gen-
eral, was closer to that of the total CHF patients than to
that of the control group. Long-term follow-up data will be
needed to conclude whether their metabolite levels are
completely normalized or not.
Mechanisms of abnormal cerebral metabolism. At
present, we are not able to explain exactly the patho-
phyisiologic mechanisms of cerebral metabolic abnormali-
ties in advanced CHF. As a possible mechanism by which
cerebral metabolism is deranged, chronic cerebral hypoper-
fusion may play a primary role (18,19). It is well known that
regional blood flow is decreased and redistributed to major
organs according to the demands in advanced CHF. This is
achieved by a complex interaction between neural, humoral
and local factors with a reduction of cardiac output. In
general, depending on the severity of heart failure, cerebral
and coronary blood flow is maintained at the expense of
renal blood flow and skeletal muscle perfusion, because
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autoregulation is well developed in these organs. However,
redistribution of regional blood flow cannot be reliably
evaluated because it is difficult to assess blood flow to several
organs simultaneously in human. We suppose that cerebral
blood flow may decrease even under resting conditions in
advanced CHF, and chronic cerebral hypoperfusion may
induce metabolic abnormalities of the brain. In addition, it
is likely that regional variations in the cerebral metabolites
may reflect regional redistribution of cerebral blood flow
and/or regional susceptibility to chronic cerebral hypoper-
fusion.
Clinical implications. Until now, psychometric analysis
has been used for evaluation of cognitive function in CHF,
but it may not be objective and accurate, because it is
affected by various biases (27,28). In contrast, 1H MRS may
provide reliable and objective metabolic information for
evaluation of cerebral function.
Cardiac transplantation is the only definitive treatment
for patients with advanced CHF. However, assessment of
prognosis in patients with CHF is very difficult because of
the extremely variable clinical course. Until now, the exer-
cise cardiopulmonary function test has been used to deter-
mine the timing of cardiac transplantation in ambulatory
patients with advanced CHF (29,30), but it has many
limitations, because exercise capacity can be influenced by
numerous noncardiac factors and exercise training. We
believe that 1H MRS may also be used to evaluate the
disease severity and prognosis of patients in CHF. Previ-
ously, the role of skeletal muscle abnormalities and evidence
of their role in exercise capacity have been extensively
studied and reviewed in CHF (5). However, little interest
has been directed toward adaptation mechanisms of the
brain in CHF despite its clinical importance. Therefore, we
propose that cerebral metabolism in CHF may be an
attractive area for further investigation in the future, and it
may provide important prognostic information. Further
studies in larger patient populations may be needed to
determine the role of 1H MRS as a screening test for
patients with a worse prognosis.
Study limitations. Several potential limitations need to be
addressed. First, psychometric analysis and biochemical
tests were not performed in this study. Therefore, we could
not evaluate the association between the cerebral metabolic
abnormalities, biochemical variables of left ventricular dys-
function and cognitive scores by psychometric measures.
Second, cerebral blood flow was not examined to investigate
regional cerebral metabolism. Positron emission tomogra-
phy may allow the study of blood flow in specific cerebral
regions and, therefore, may be used in conjunction with 1H
MRS to obtain simultaneous information on cerebral blood
flow and cerebral metabolism. Third, most patients were
taking standard medication for treatment of CHF and,
therefore, drug effects on cerebral metabolites could not be
evaluated. Finally, the regions of OGM may not exclude
contamination from white matter or cerebrospinal fluid,
because it is difficult to select 8 to 10 ml of pure OGM.
However, placing localization voxel was carefully performed
in the same region for all subjects to increase consistency of
the region selected.
Conclusions. On the basis of our findings, we conclude
that cerebral metabolism is abnormally deranged on 1H
MRS in advanced CHF, and it may be used as a potential
marker of the disease severity.
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